| Apalutamide | Janssen Pharma | ||
| 60 mg; Tablets |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer. | |||
|
Yes
| |||
| Erleada | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | **** *** | **** *** | **** *** | *** ** ** (****** *** **********) | **** ** *** **, **** | **** *** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* (***** ******) | ******* (***** ******) |
| ***** ****** | ******* ***** ******** ******** | ******* ***** ******** ******** | ******* ***** ******** ******** | *** ** ** (****** *** **********) | **** ** *** **, **** | ******* ***** ******** ******** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | ******* (***** ******) |
| ****** | ******* ***** ******** ******** / ***** *** ********** ***** | ******* ***** ******** ******** / ***** *** ********** ***** | ******* ***** ******** ******** | *** ** ** (****** *** **********) | ********* ********* ********* | ******* ***** ******** ******** | ********* ********* ********* | ********* ********* ********* | ********* ********* ********* | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** / ********* | *** **, **** | ******* / ********* *** | ********* ******** | ******* **** **** *** *** **** |
| ***** ****** | *** / ********* | *** **, **** | ******* / ********* *** / ******* | ******** | ******* *** **** *** *** **** |
| ****** | *** / ********* | *** **, **** | ******* / ********* *** | ********* ******** | ******* *** **** *** *** **** |
| Apalutamide | Janssen Pharma | ||
| 240 mg ; Tablet |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer. | |||
|
Yes
| |||
| Erleada | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* (***** ******) | ******* (***** ******) |
| ******** ******** ********* *** *** ********* ** ******** ****** *** ******** ********-********** ******** | ******** ******** ********* *** *** ********* ** ******** ****** *** ******** ********-********** ******** | *********** ***************** ** ******** ******** ********** | *********** ***** ** ** ******** ******** ********* | ****-********* *** *** ********* ** ***-********** ********-********* ******** ****** | *********** ***************** ** ******** ******** ********** | ****-********* *** *** ********* ** ***-********** **********-********* ******** ****** | ****-********* *** *** ********* ** ***-********** ********-********* ******** ****** | ****-********* *** *** ********* ** ********** **********-********* ******** ****** | ****-********* *** *** ********* ** ***-********** ********-********* ******** ****** | ********** ************ | ****-********* *** *** ********* ** ********** **********-********* ******** ****** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ ********* | *** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|